Valley National Advisers Inc. Sells 1,192 Shares of Johnson & Johnson (NYSE:JNJ)

Valley National Advisers Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.3% during the second quarter, Holdings Channel.com reports. The fund owned 6,614 shares of the company’s stock after selling 1,192 shares during the period. Valley National Advisers Inc.’s holdings in Johnson & Johnson were worth $966,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson in the first quarter valued at about $31,000. WFA Asset Management Corp raised its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $44,000. Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE:JNJ opened at $159.39 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.39. The company has a market capitalization of $383.60 billion, a PE ratio of 9.94, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The business has a fifty day moving average price of $152.38 and a two-hundred day moving average price of $153.14. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.80 earnings per share. Analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.